SANTA CRUZ DE TENERIFE, March 24. (EUROPE PRESS) –
The Governing Council authorized this Thursday the Ministry of Health to spend 10,019,310 euros on the acquisition of a supply of 360,350 doses of vaccines included in the current calendar in the Autonomous Community of the Canary Islands for all ages of life .
The acquisition of this supply is derived from the Framework Agreement for the selection of companies supplying calendar vaccines and others existing between the General State Administration, the Cities of Ceuta and Melilla and several Autonomous Communities, to which the Canary Islands adhered in 2021.
According to this procedure, it is up to the Autonomous Community of the Canary Islands to acquire the estimated necessary vaccine units exclusively from the supply companies awarded the said Framework Agreement, in accordance with the terms established therein.
Likewise, it is responsible for awarding the contracts in accordance with the procedure established in article 221.4 of Law 9/2017, of November 8, on Public Sector Contracts and the provisions of the specifications that govern the procedure, and communicate to the Ministry of Health the number of vaccines purchased for each batch.
In this sense, the General Directorate of Public Health of the Canary Health Service estimates that for the development during 2022 of the vaccination calendar for all ages of life in the Canary Islands, it is necessary to acquire a supply consisting of 30,000 doses of Hexavalent vaccine against hepatitis B, diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis, and Haemophilus influenzae type B conjugate; 15,000 doses against diphtheria, tetanus, acellular pertussis, and inactivated poliomyelitis; 20,000 doses against diphtheria, tetanus, acellular pertussis with reduced antigenic content; 45,000 doses against diphtheria and tetanus with reduced antigenic content; 2,000 doses against hepatitis B for pediatric age; 5,000 doses against hepatitis B for adults; 30,000 doses against measles, rubella and mumps; 30,000 doses against chicken pox; 25,000 doses against measles, rubella, mumps and chicken pox; 25,000 doses of conjugate vaccine against meningococcus C; 38,000 doses against meningococcus serogroups A,C,Y,W; 40,000 doses against meningococcus serogroup B; 35,000 doses against 9-valent human papillomavirus (HPV); 20,000 doses of 23-valent pneumococcal polysaccharide vaccine and 350 doses of rotavirus vaccine.
